|Page (1) of 1 - 03/21/14||email article||print page|
Cellular Dynamics Announces Presentations at the SOT Annual Meeting Highlighting Use of iPSC-Derived Human Cells for Environmental Toxicology and Drug Toxicity Testing(March 21, 2014)
MADISON, Wis., March 21, 2014 (GLOBE NEWSWIRE) -- Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced scientific presentations at the Society of Toxicology's 53nd Annual Meeting (SOT), March 23 to 27 in Phoenix.
Multiple presentations, symposia and workshops demonstrate the expanding utility of CDI's iCell® products on toxicology assay development.
Several presentations describe research in the area of environmental toxicology; this highlights the expanding utility of CDI's iCell and MyCell® Products outside of their traditional use in pharmaceutical toxicity testing and basic human biological research.
Chris Parker, chief commercial officer of CDIsaid, "Our pharmaceutical and life science customers continue to find new ways to apply our iCell and MyCell Products to their drug development and research priorities. What is especially exciting for us is the increasing use of our cells outside of the life sciences. Several presenters at this year's SOT meeting describe environmental toxicology applications for our cells. Along with our recently announced collaboration with Nestlé, who are using our cells for nutritional research, the application of our cells in multiple scientific disciplines validates CDI's scientific and commercial mission."
Environmental Toxicology Presentations:
"Induced Pluripotent Stem Cell-derived Neurons as a Human Model for Testing Environmentally-induced Developmental Neurotoxicity," presented by IL Druwe, US EPA, within the "Induced Human Pluripotent Stem Cells and Their Differentiated Progeny Cells: Implementation in Toxicity Testing" symposium, March 24, 9:15 am - 12:00 p.m.
"Phenotypic In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using Human iPSC-derived Cardiomyocytes," exhibitor-hosted session presented by CDI on NIEHS/NIH and pharmaceutical toxicity testing data, March 25, 1:30 - 2:30 pm
"In Vitro Assessment of Cardiotoxicity Hazard of Environmental Compounds Using Fast Fluorescence Imaging of Beating iPSC-derived Cardiomyocytes," poster presented by O Sirenko on NIEHS/NIH data, March 26, 9:00 am - 12:30 pm, Abstract 1616g
A list of presentations and posters to be given by numerous investigators using CDI's iCell and MyCell Products can be found at http://www.cellulardynamics.com/sot/posters.html.
About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications. CDI's proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in the research and development of cellular therapeutics. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin, with a second facility in Novato, California. See www.cellulardynamics.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Cellular Dynamics International, Inc., including statements regarding our products, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our product development efforts, actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Cellular Dynamics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Cellular Dynamic's annual report on Form 10-K/A filed with the Securities and Exchange Commission on March 11, 2013, which risks are incorporated herein by reference, and as may be described from time to time in Cellular Dynamics' subsequent SEC filings.
Senior Director, Marketing & Communications
Cellular Dynamics International, Inc.
Robert E. Flamm, Ph.D.
Russo Partners LLC
Gitanjali Jain Ogawa
The Trout Group, LLC
Related Keywords: BIOTECHNOLOGYPro AV, Post/Production, Management, Presentors, Management, Director, Business, Marketing, Business Issues, Presentation, Marketing, Events, OS (Operating System), Inc., Science, Environmental Technology, Communications Technology, Medical, Biology, Stem Cell, Business, Science, Other,